Division of Gastroenterology, Department of Internal Medicine, Pancreatic Cancer Center, University of Michigan Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; Gastroenterology Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Biomedical Engineering, Cornell University, Ithaca, New York.
Gastroenterology. 2014 Mar;146(3):647-51. doi: 10.1053/j.gastro.2013.12.007. Epub 2013 Dec 13.
Hematogenous dissemination is thought to be a late event in cancer progression. We recently showed in a genetic model of pancreatic ductal adenocarcinoma that pancreas cells can be detected in the bloodstream before tumor formation. To confirm these findings in humans, we used microfluidic geometrically enhanced differential immunocapture to detect circulating pancreas epithelial cells in patient blood samples. We captured more than 3 circulating pancreas epithelial cells/mL in 7 of 21 (33%) patients with cystic lesions and no clinical diagnosis of cancer (Sendai criteria negative), 8 of 11 (73%) with pancreatic ductal adenocarcinoma, and in 0 of 19 patients without cysts or cancer (controls). These findings indicate that cancer cells are present in the circulation of patients before tumors are detected, which might be used in risk assessment.
血行播散被认为是癌症进展的晚期事件。我们最近在胰腺导管腺癌的遗传模型中表明,在肿瘤形成之前,可以在血液中检测到胰腺细胞。为了在人类中证实这些发现,我们使用微流控几何增强差异免疫捕获法在患者的血液样本中检测循环胰腺上皮细胞。我们在 21 名囊性病变且无癌症临床诊断(仙台标准阴性)的患者中有 7 名(33%)、11 名胰腺导管腺癌患者中有 8 名(73%)和 19 名无囊肿或癌症患者中(对照组)的 0 名患者中捕获了超过 3 个/mL 的循环胰腺上皮细胞。这些发现表明,在肿瘤被检测到之前,癌细胞就已经存在于患者的血液中,这可能用于风险评估。